Charles Vega, MD, FAAFP

Addressing Access Barriers in Colorectal Cancer Screening

In this episode, ‘Addressing Access Barriers in Colorectal Cancer Screening,’ the panelists explore common patient concerns about the cost of colonoscopy following a positive colorectal cancer screening test. The speakers clarify that stool-based screening tests and subsequent diagnostic colonoscopy are generally covered by insurance, including procedures involving polyp removal and surveillance. They emphasize that financial worries, along with time off work and logistical challenges, can significantly reduce adherence. The discussion also highlights the growing role of health systems in addressing social drivers of health, such as transportation assistance and patient navigation services. Ultimately, the faculty underscore the importance of proactively addressing cost and access concerns to improve screening completion rates and reduce colorectal cancer disparities.

The next episode in this series, ‘Coordinating Care After Abnormal Colorectal Cancer Results,’ focuses on the importance of timely follow-up after a positive stool test, ideally within six months, closing the referral loop to gastroenterology, avoiding inappropriate stool testing in symptomatic patients, and ensuring that noticeable symptoms prompt direct diagnostic evaluation rather than screening.

Videos

Positive stool test? Learn why follow-up colonoscopy is often covered and how clinics tackle cost, time-off, and transport barriers.

 Individualizing When to Stop Colorectal Cancer Screening 

This episode, titled ‘Individualizing When to Stop Colorectal Cancer Screening,’ examines the nuanced decision-making involved in determining when to discontinue colorectal cancer screening. While guidelines generally recommend screening from ages 45 to 75, faculty emphasize the importance of individualizing decisions based on overall health, life expectancy, and patient preferences. The discussion highlights that screening may remain appropriate for robust older adults, while it may not benefit patients with limited life expectancy due to advanced comorbid conditions. Speakers underscore the importance of framing conversations around overall health priorities rather than age alone, using shared decision-making to guide recommendations. Ultimately, the segment reinforces that stopping screening is not a rigid cutoff but a thoughtful, patient-centered clinical judgment.

In the next episode, ‘Addressing Access Barriers in Colorectal Cancer Screening,’ panelists will continue their discussion on colorectal cancer screening and address financial concerns related to follow-up colonoscopy after a positive screening test, emphasizing that most costs are covered by insurance and that removing financial misconceptions can improve adherence. The discussion also highlights the broader impact of social determinants of health, such as transportation, time off work, and childcare, and the role of patient navigation in improving screening completion rates.

See how FIT cutoffs change accuracy, why Cologuard raises sensitivity

Individualizing When to Stop Colorectal Cancer Screening

Overcoming Barriers and Advancing Precision in Colorectal Cancer Screening 

In ‘Overcoming Barriers and Advancing Precision in Colorectal Cancer Screening,’ our experts delve into the ongoing challenges and future directions in colorectal cancer screening implementation. The discussion highlights persistent barriers to screening uptake, including access to care, follow-through after noninvasive testing, and disruptions caused by the COVID-19 pandemic. Faculty emphasize the value of patient navigation and mailed outreach programs in improving screening rates and closing care gaps. The conversation also examines how evolving technologies, including blood-based testing and machine learning–driven precision risk models, may reshape screening paradigms. Finally, the speakers consider the potential for risk-stratified approaches and evolving age recommendations as the field works toward more personalized and effective colorectal cancer prevention strategies.

Our next episode, ‘Individualizing When to Stop Colorectal Cancer Screening,’ features panelists discussing individualized decisions about when to stop colorectal cancer screening based on age, comorbidities, life expectancy, and patient preference, emphasizing shared decision-making, particularly for adults over 75 and those with limited life expectancy.

Learn how FIT, Cologuard, blood tests and colonoscopy compare on accuracy, follow-up timing, and easier prep options for screening.

Comparing Colorectal Cancer Screening Test Performance and Prep Option

In this episode, ‘Comparing Colorectal Cancer Screening Test Performance and Prep Options,’ the panelists review the performance characteristics of available colorectal cancer screening modalities, including colonoscopy, FIT, multi-target stool DNA, RNA-based tests, and blood-based assays. The faculty compare sensitivity and specificity across tests, emphasizing that colonoscopy remains the most sensitive and uniquely therapeutic option. They highlight variability in FIT performance depending on assay type and cutoff thresholds, underscoring the importance of understanding which test is being used. Advances in next-generation stool DNA testing are discussed, with improved sensitivity and specificity compared to earlier versions. The conversation also addresses practical considerations such as bowel preparation options, patient adherence, and tailoring prep regimens to comorbidities to optimize both safety and diagnostic quality.

The next episode in this series, ‘Overcoming Barriers and Advancing Precision in Colorectal Cancer Screening,’ features expert faculty reviewing the barriers to colorectal cancer screening uptake, the evolving role of blood- and DNA-based testing, and the ongoing discussions around precision risk stratification and potentially lowering the screening age amid rising early-onset disease globally.

Clinicians share practical tips to boost colorectal screening, comparing colonoscopy and stool tests while addressing fears.

Charles Vega, MD, FAAFP

Articles